Newsletter

Exela Technologies Gets $90 Million Contract Award with Major US Health Insurer

Exela Technologies, Inc. (XELA) announced on March 9 that the company received a new $90 contract with a major US health insurance company. Exela Technologies is a global leader in business process automation and launched its PCH Global platform in September 2020 to combine its services with the power of automation technology and SaaS. This […]

0Comments

KemPharm gets FDA Approval for AZSTARYS™ to Treat ADHD

On March 2, KemPharm, Inc. (KMPH) announced that the FDA approved its New Drug Application (NDA) for the drug AZSTARYS™ (formerly referred to as KP415). The drug is a once-daily treatment for patients six-years-old and above who have attention deficit hyperactivity disorder (ADHD). AZSTARYS™ should be available as early as the second half of 2021 […]

0Comments

Affiliates of New Mountain Capital Acquire Aegean Corporation

Aegean Corporation (AEGN) announced on February 16 that the company entered into a definitive agreement for an acquisition by affiliates of New Mountain Capital, LLC. Aegean’s stockholders will receive a cash payout of $26 per share, which is a 28% premium over the stock’s 30-day moving average price. The deal values the enterprise at $963 […]

0Comments

Gilat Satellite Networks Awarded Contract for Telecom Systems at Peruvian Airports

Gilat Satellite Networks, Ltd. (GILT) announced on February 4 that the company was awarded a multi-million-dollar contract. Under the terms of the contract, Gilat will provide mission telecom systems for 29 airports in Peru. Gilat, a global leader in satellite-based broadband communications, has successfully completed several other large government projects in Peru.   Jet Equities […]

0Comments

Sorrento Therapeutics Reports Promising Phase 1b Results of COVI-MSC in COVID ICU Patients

On January 26, Sorrento Therapeutics, Inc.  (SRNE) announced preliminary results from a Phase 1b study of COVID-MSC for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). COVI-MSC is an infusion treatment of human allogeneic adipose-derived mesenchymal stem cells. The three patients in the study experienced no infusion-related adverse effects […]

0Comments

IZEA Lands Seven-Figure Contract Award

On January 12, IZEA Worldwide, Inc. (IZEA) announced that the company received a seven-figure contract award from a Fortune 100 retailer. The retailer is an existing client that expanded its marketing program with IZEA through 2021. Under the terms of the contract, IZEA will provide managed services and licensing of IZEA’s BrandGraph software. IZEA is […]

0Comments